High-sensitivity cardiac troponin I and risk of dementia: 25-year longitudinal study in 1 the Whitehall II cohort 2

3

Yuntao Chen^{ab}, Martin Shipley^a, Atul Anand^c, Dorien M Kimenai^c, Klaus P Ebmeier^d, 4

- Severine Sabia^{ae}, Archana Singh-Manoux^e, John Deanfield^f, Mika Kivimaki^a, Gill 5
- Livingston^a, Nicholas L Mills^{cg}, Eric J Brunner^b 6
- 7
- a Division of Psychiatry, University College London, London, UK 8
- 9 b Department of Epidemiology and Public Health, University College London, London, UK
- c British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, 10
- 11 Edinburgh, UK
- d Department of Psychiatry and Wellcome Centre for integrative Neuroimaging, University 12 13 of Oxford, Oxford, UK
- e Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Universite de 14
- 15 Paris, Paris, France
- f Institute of Cardiovascular Science, University College London, London, UK 16
- 17 g Usher Institute, University of Edinburgh, Edinburgh, UK
- 18
- Correspondence to: 19
- 20 Yuntao Chen
- Division of Psychiatry, University College London, London, UK 21
- 22 Maple House, 149 Tottenham Court Road, London, W1T TNF
- 23 Email address: yuntao.chen@ucl.ac.uk
- 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract 25

26

27 **Objective** We hypothesise that subclinical myocardial injury during midlife, indexed by increases in cardiac troponin I, is associated with accelerated cognitive decline, smaller 28 29 structural brain volume, and higher risk of dementia.

30

Design Longitudinal cohort study 31

32

33 Setting Civil service departments in London (Whitehall II study)

34

35 Participants 5985 participants aged 45-69 had cardiac troponin I measured by highsensitivity assay at baseline (1997-99) for prospective cohort analyses. A nested case-control 36 37 sample of 3475 participants (695 dementia cases and 2780 matched controls) was used for backward cardiac troponin I trajectory analysis. 641 participants provided magnetic 38 resonance imaging (MRI) scans for brain volume analysis. 39

40

41 Main outcome measures Incident dementia cases were ascertained from national hospital episode statistics, mental health and mortality registers until 2023. Cognitive testing was 42

performed at six waves over 25 years (1997-99, 2002-04, 2007-09, 2012-13, 2015-16, 2019-43 22). Brain volume metrics were derived from structural MRI scans (2012-16).

44 45

46 **Results** For prospective cohort analyses, 606 (10.1%) incident cases of dementia were

recorded over a median follow-up of 24.8 years. Doubling of cardiac troponin was associated 47

48 with 11% higher risk of dementia (HR=1.11, 95% CI: 1.04 to 1.19). Participants with

49 increased cardiac troponin at baseline had a faster decline of cognitive function with age.

50 Compared to participants with concentrations below the limit of quantitation (<2.5 ng/L),

those in the upper third (>5.2 ng/L) had similar global cognitive z score at age 60, but had 51

52 0.10 (95% CI: 0.02 to 0.18) standard deviations lower score at age 80, and 0.19 (0.03 to 0.35) 53 standard deviations lower score at age 90. Participants with dementia had increased cardiac

troponin concentrations compared with those without dementia between 7 and 25 years 54

before diagnosis. Compared to those with low cardiac troponin level (<2.5 ng/L at baseline) 55

56 those with concentrations >5.2 ng/L had lower grey matter volume and higher hippocampal

atrophy 15 years later, equivalent to ageing effects of 2.7 and 3 years, respectively. 57

58

59 **Conclusions** Subclinical myocardial injury at midlife was associated with higher dementia

- risk in later life. 60
- 61

What is already known on this topic 62

A systematic review of observational studies suggests higher cardiac troponin concentrations 63 64 are associated with poorer cognitive function and increased dementia risk. Formal metaanalysis was not performed due to the small number of available studies. 65 66 Existing studies assessed cardiac troponin once and had relatively short follow-up time. 67 Evidence is lacking on the time course of cardiac troponin level before diagnosis in dementia 68 69 cases compared with controls. 70 71 72 What this study adds People with increased cardiac troponin I concentrations in mid-life had faster cognitive 73 74 decline and were more likely to develop dementia over 25 years of follow-up. Backward trajectory analysis using three measurements using a high-sensitivity assay showed that 75 people with dementia had higher cardiac troponin levels as early as 25 years before dementia 76 diagnosis compared with those without dementia. People in the magnetic resonance imaging 77 78 subcohort with higher cardiac troponin I concentrations at baseline had lower grey matter 79 volume and hippocampal atrophy 15 years later. 80 81 Subclinical myocardial injury in midlife, by indicating long-term risk of dementia, is unlikely to be due to preclinical changes before dementia onset and may lie on the causal pathway to 82 dementia.

84

85

86 Introduction

Emerging evidence suggests an intertwined relation between the health of heart and brain.^{1–3}
The 2024 Lancet Commission on dementia suggests 17% of dementia cases can be prevented
or delayed by modifying cardiovascular risk factors including high cholesterol, physical
inactivity, diabetes, hypertension, obesity, smoking and excessive alcohol consumption.⁴
People with poor cardiovascular health, even in the absence of clinical coronary heart disease,
have increased risk of dementia.^{5,6}

93

94 Cardiac troponin is a commonly-used cardiac biomarker and its utility has been extended with introduction of high-sensitivity assays.^{7–9} Modest elevation in cardiac troponin in 95 apparently healthy populations is linked with increased risk of dementia, although existing 96 studies have only assessed cardiac troponin once and had relatively short follow-ups.^{10–12} 97 Consequently, it is unknown how long before dementia diagnosis cardiac troponin levels 98 become increased among cases relative to controls. Further, few studies have prospectively 99 examined whether cardiac troponin in midlife is a marker of potential preclinical changes in 100 101 dementia-related measures such as cognition and brain volume. Consistent results from these different lines of research would strengthen the evidence on the role of subclinical 102 103 myocardial injury in the aetiology of dementia.

104

This study uses longitudinal data from the Whitehall II cohort study spanning 25 years and three measurements of cardiac troponin I based on a high-sensitivity assay. We examined 1) the long-term association of cardiac troponin I at study baseline with cognitive trajectory and incident dementia in prospective analyses; 2) how long before diagnosis of dementia the cardiac troponin I level has been elevated by modelling the backward trajectory of cardiac troponin I; and 3) the association of cardiac troponin I with brain volume measures assessed 15 years later in a substudy of structural magnetic resonance imaging.

112

113 Methods

114 Study population

The Whitehall II study is an ongoing longitudinal study of 10 308 people recruited from the
British Civil Service in 1985-88. Participants had clinical examinations of behavioural and

biomedical factors in 8 waves (1985-88, 1991-94, 1997-99, 2002-04, 2007-09, 2012-13,

118 2015-16, 2019-22). Written informed consent from participants was renewed at each contact.

119 The baseline for this study is 1997-99 when cardiac troponin was first measured. We

included 6 waves of clinical examination until 2022. Disease and death data up to March

- 121 2023 were obtained through linkage to electronic health records of the UK National Health
- 122 Service.
- 123

124 Measures

125 High-sensitivity cardiac troponin I

- 126 Cardiac troponin I was measured using stored blood samples at three waves (1997-99, 2007-
- 127 09, 2012-13).^{9,13} Blood samples for each wave were handled according to a standardised
- 128 protocol. Fasting venous blood samples were collected, centrifuged, and serum was stored in
- 129 aliquots at -80 °C until batch analysis was performed. Cardiac troponin I concentrations were
- 130 measured using the Siemens Atellica Immunoassay High Sensitivity Troponin I assay
- 131 (Siemens Healthineers, Erlangen, Germany). This assay has a limit of blank of 0.5 ng/L, limit
- of detection of 1.6 ng/L, and a limit of quantitation of 2.5 ng/L. In the analyses, we assigned
- 133 0.5 ng/L to those with cardiac troponin concentration below the limit of blank. The sex-
- specific 99th centile upper reference limits in the general population used for clinical referral
- are 34 ng/L and 53 ng/L in females and males, respectively.
- 136

137 **Cognitive function**

was allowed for each test.

- 138The cognitive test battery was introduced to the Whitehall II clinic in 1997-99 and repeated at
- all subsequent clinical assessments. We included all six waves of cognition data between
- 140 1997 (aged 45-69 years) and 2022 (aged 68-92 years). The tests have good test-retest
- reliability (range 0.6-0.9), assessed in 556 participants and retested within three months in
- 142 1997-99. Three cognitive domains (memory, executive function, and fluency) were assessed.
- 143 Memory was assessed using a 20-word free recall test. Executive function was assessed with
- the Alice Heim 4-I test. Fluency was assessed using measures of phonemic and semantic
- 145 fluency. Participant were asked to recall in writing as many words beginning with "s"
- 146 (phonemic fluency) and as many animal names (semantic fluency) as they could. One minute
- 147 148
- Based on three cognitive domains, we created a global cognitive score incorporating all tests
 described above by firstly using the distribution of the first wave of cognitive data (1997-99)
- to standardise the raw scores for each domain to z scores. We summed these z scores and

restandardised them to yield the global score, an approach that minimises measurement error
 inherent individual tests.¹⁴

154

155 Dementia

We used three registers (the national hospital episode statistics (HES) database, the Mental Health Service Data Set, and the mortality register) to ascertain dementia using ICD-10 codes F00-F03, F05.1, G30, and G31. Record linkage was available up to 1 March 2023. Date of dementia was set as the earliest record of a diagnostic code for dementia in any of the three ascertainment databases. As our outcome was incident dementia, participants with dementia at baseline were excluded.

162

164

163 Brain volume

165 multimodal brain magnetic resonance imaging (MRI) scans at the Oxford Centre for

771 participants, randomly selected from Whitehall II phase 11 (2012-13), received

166 Functional MRI of the Brain, as part of the Whitehall II imaging substudy.¹⁵ Due to a scanner

upgrade, two MRI scanners were used: a 3T Siemens Magnetom Verio scanner (Erlangen,

168 Germany) with a 32-channel head coil (April 2012 to December 2014) and a 3T Siemens

169 Prisma Scanner (Erlangen, Germany) with a 64-channel head-neck coil in the same centre

170 (July 2015 to December 2016). The scan parameters were identical or closely matched

between scanners. Analyses were adjusted for scanner type. Brain tissues were segmented

using an automated segmentation tool, which extracts measures of total grey matter, white

173 matter, and cerebrospinal fluid.¹⁵ Intracranial volume was calculated as the sum of total grey

174 matter, white matter, and cerebrospinal fluid. All volumes were normalised by converting

them to percentages of the intracranial volume. Burden of white matter hyperintensities was

estimated using the Fazekas visual rating scale.¹⁶ A score (range 0-3) was assigned for deep

177 white matter and periventricular areas based on the size, location, and confluence of lesions.

178 We used the sum of the two scores to estimate the total burden of white matter intensities.

179 Hippocampal atrophy was estimated using the Scheltens score assessed by three clinicians

180 independently.¹⁷

181

182 Clinical characteristics

183 We included sociodemographic, health behaviours, and health status at baseline (1997-99) as

184 covariates: age, sex, education (less than secondary school, secondary school, university),

185 occupational position based on British Civil Service employment grade (administrative

grades, professional or executive grades, clerical or support grades), birth cohort defined 186 based on sociohistorical events¹⁸ (Depression-era cohort born 1930-38, World War 2 cohort 187 born 1939-45, Post-war cohort born 1946-52); smoking status (never, former, current), 188 alcohol consumption (non-drinker, moderate consumption: 1-14 units/week in women or 1-189 21 units/week in men, heavy consumption: >14 units/week in women or >21 units/week in 190 men), physical activity (hours of moderate or vigorous exercise/week, categorised as low <1 191 hour, moderate 1-2.4 hour, high >2.5 hour); body mass index (BMI, kg/m²), systolic blood 192 pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), fast glucose (mmol/l), total 193 194 cholesterol (mmol/L), diabetes (doctor-diagnosed diabetes or use of diabetes medication). Cardiovascular disease was identified via linkage to national hospital episode statistics (HES) 195 data, recording any diagnosis of coronary heart disease (ICD-9 codes 410-414 and 429; ICD-196 10 codes I20-I25) or stroke (ICD-10 codes I60-I64 and G45). 197

198

202

199 **Statistical analysis**

Association between cardiac troponin I at baseline and incidence of dementia. 200

- 201 We included all participants free of dementia or cardiovascular disease, who had data on
- 203 record of dementia, death, or 1 March 2023, whichever came first. Cox proportional hazard

cardiac troponin I at baseline (1997-99). These participants were followed-up to date of

- models were used to examine the association between cardiac troponin I and dementia 204
- 205 incidence. We modelled cardiac troponin I both continuously and categorically. For the
- continuous analysis, we used log2 transformation as the cardiac troponin levels were right-206
- 207 skewed. For the categorical analysis, we used the following categories: <2.5 ng/L (below the
- limit of quantitation threshold, reference group), 2.5-3.4 ng/L, 3.5-5.2 ng/L, >5.2 ng/L. The 208
- latter three groups were cut based on tertiles of troponin measurements above the limit of 209
- quantitation threshold. We also modelled cardiac troponin I using natural cubic spline 210
- function to visualise possible non-linear association with dementia incidence. In the above 211
- analyses, we used age as time scale and adjusted for sex, ethnicity, education level, 212
- occupational position, alcohol consumption, smoking status, physical activity, BMI, SBP, 213
- DBP, glucose, and total cholesterol at baseline. 214
- 215
- Association between cardiac troponin I at baseline and cognitive trajectory. 216
- We included all participants that were free of dementia and cardiovascular disease at baseline, 217
- had data on cardiac troponin I at baseline, and had at least one measurement of cognitive 218
- function among 6 repeated measurements between 1997 and 2022. Mixed models with age as 219

the time scale were used to examine whether cardiac troponin I at baseline was associated 220 with cognitive trajectories. The model included sex, ethnicity, education level, occupational 221 position, birth cohort, cardiac troponin I (log₂ transformed), age, age², and interactions of all 222 the covariates with age and age². A likelihood ratio test was conducted for the interaction of 223 cardiac troponin I with age and age² to examine whether the cognitive trajectory differed in 224 different cardiac troponin I levels at baseline. We replicated the analysis using categorised 225 cardiac troponin I in 4 groups as above to relax the linear assumption and to visualise and 226 present the results. We plotted the cognitive trajectory by different baseline cardiac troponin 227 228 level, and statistically compared cognitive scores for different troponin I groups at age 60, 70, 80, and 90. We repeated the analysis by further accounting for alcohol consumption, smoking 229 status, physical activity, BMI, SBP, DBP, glucose, and total cholesterol. 230

231

Backward trajectory of cardiac troponin I before dementia. 232

We included all participants who were free of dementia and cardiovascular disease at 233 baseline and had at least one cardiac troponin measurement before end of follow-up. We used 234 a nested case-control design to compare the trajectory of cardiac troponin I in those who 235 developed dementia and those did not. Each dementia case was matched to 4 controls at the 236 237 diagnostic date. We used random sampling with replacement (i.e., same control is possible to be matched with different cases). The eligibility of the control sample is: 1) free of dementia 238 at the diagnostic date; 3) of similar sex and age $(\pm 3 \text{ years})$; 4) of same education level. In the 239 sensitivity analysis, we further matched with same cardiovascular disease to see whether the 240 241 effect was attenuated.

242

We used retrospective time since the matching date as the time scale. Time 0 was date of 243 dementia diagnosis for each quintet (1 case and 4 matched controls). A latent process mixed 244 model¹⁹ was used to model the trajectory of cardiac troponin I (log2 transformed). The model 245 included time, time², index age (age at time 0), sex, education level, case indicator (coded as 246 1 for cases and 0 for controls), and interactions of all the covariates (index age, sex, education 247 level, and case indicator) with time and time². Wald test was used for the interaction of case 248 indicator with time and time² to examine whether the trajectory of cardiac troponin I differed 249 between cases and controls. We also used the Wald tests to compare the differences of 250 predicted mean cardiac troponin I levels between cases and controls at different time points 251 before dementia diagnosis. 252

254 Association between cardiac troponin I at baseline and brain volume.

- We included participants that were free of dementia and cardiovascular disease, did not have 255 missing data for cardiac troponin I at phase 5 (1997-99), and had MRI scans between 2012-256 16. Linear regression models were used to examine the association between cardiac troponin 257 I at baseline and whole brain volume (sum of grey and white matter), grey matter volume, 258 and white matter volume. Poisson regression models were used to examine the association of 259 baseline cardiac troponin I with white matter hyperintensity burden and hippocampal atrophy. 260 We modelled cardiac troponin I both continuously and categorically aforementioned. The 261 262 models were all adjusted for age at MRI assessment, sex, education, occupational position,
- 263 264
- 265 We used simple imputation for the covariates with missing values. All analyses were
- 266 performed using R statistical software, version 4.4.1.

smoking status, and alcohol consumption.

267

268 Patient and public involvement

- 269 Participants of the Whitehall II study were not involved in setting the research question or the
- 270 outcome measures, nor in developing plans for recruitment, design, or implementation of the
- study. No participants were asked for advice on interpretation or writing up of results.
- However, all results are disseminated to study participants via newsletters and our website,
- which has a participant portal (https://www.ucl.ac.uk/psychiatry/research/mental-health-
- 274 older-people/whitehall-ii/participants-area).

275

276 **Results**

7299 participants had at least one measure of cardiac troponin I. They did not have dementia 277 at baseline. After excluding participants with cardiovascular disease (n=62) at baseline, 7237 278 participants were included. Among these participants, 5985 had cardiac troponin at baseline. 279 280 606 (10.1%) cases of dementia were recorded over a median follow-up time of 24.8 (interquartile range 23.3-25.1) years. Baseline characteristics, as well as by cardiac troponin I 281 282 levels and dementia status at follow-up, are presented in Table 1. Participants with higher cardiac troponin I were older, more likely to be men and from higher educational and 283 occupational group. They had higher BMI, SBP, DBP, and glucose level. Compared with 284 those who were dementia free at the end of follow-up, people with incident dementia were 285

older, more likely to be women, and from lower education and occupational group. They hadhigher BMI, glucose, SBP and total cholesterol level.

288

289 Association between cardiac troponin I at baseline and incidence of dementia

5985 participants free of diagnosed cardiovascular disease and dementia at baseline (age
range 45-69) were included in the analyses. Every doubling of cardiac troponin I was
associated with 11% higher risk of dementia (HR=1.11, 95% CI: 1.04 to 1.19). The

- association did not differ between age group ($\leq 60 \text{ vs} > 60 \text{ years}$) (P_{interaction}=0.76) or sex
- 294 (P_{interaction}=0.32). Compared with those with cardiac troponin I below quantification limit

295 (<2.5 ng/L), participants with cardiac troponin I >5.2 ng/L had 43% higher risk of dementia

296 (HR=1.43, 95% CI: 1.13 to 1.80) (Table 2). We also plotted the association between cardiac

troponin I and dementia incidence using natural cubic splines (Figure S1). The result was

298 consistent with analysis with categorised cardiac troponin I group and showed continuously

299 increased risk of dementia as cardiac troponin I increases. The increase in dementia risk

tended to be smaller as troponin I level increased, however this was not a statistically

- 301
- 302

303 Association between cardiac troponin I at baseline and cognitive trajectory

significant effect (P for non-linearity=0.22).

5895 participants free of diagnosed cardiovascular disease and dementia at baseline with one 304 or more measurements of cognitive data were included in the analyses (90 participants 305 without any cognitive data were excluded). Of them, 2508 (42.5%) had cognitive data at all 306 six waves, 1102 (18.7%) at five waves, 652 (11.1%) at four waves, 555 (9.4%) at three waves, 307 500 (8.5%) at two waves, and 578 (9.8%) at only one wave. Cognitive trajectory differed by 308 cardiac troponin I after adjusting for sex, ethnicity, education level, occupational position, 309 310 birth cohort (continuous values: P_{interaction}=0.07; grouped values: interaction P=0.0012). Participants with higher cardiac troponin I at baseline had a faster decline of cognitive 311

function with age (Figure 1). Compared with participants with cardiac troponin I <2.5 ng/L,

those with cardiac troponin I >5.2 ng/L had similar global cognitive z score at age 60, but had

- 0.10 (0.02 to 0.18) standard deviations lower global cognitive z score at age 80, and 0.19
- 315 (0.03 to 0.35) standard deviations lower score at age 90 (Table 3). Results were similar after

further adjusting for behavioural and biomedical risk factors at baseline (Figure S2, Table S1).

317

318 Backward trajectory of cardiac troponin I before dementia

Among the 695 incident dementia cases identified in the study sample, all were successfully 319 matched to 4 controls and this led to a nested case-control sample of 3475 individuals. Both 320 case and control groups had an increasing predicted cardiac troponin I level over time, which 321 were not significantly different, though they tended to converge (interaction P=0.12) (Figure 322 2). Compared with controls, cases had consistently higher mean cardiac troponin I levels 323 324 from 25 years to 7 years preceding dementia diagnosis (Table S2). Further matching by cardiovascular disease status showed similar but attenuated results (Figure S3, Table S3). 325 326 327 Association between cardiac troponin I at baseline and brain volume Of the 771 participants in the substudy, we excluded those without a cardiac troponin I 328

measurement (n=129), or who had dementia or cardiovascular disease at baseline (n=1), 329

producing an analytical sample of 641. One year older age was associated with 0.32% 330

(95%CI: 0.28 to 0.35%) lower total brain volume, 0.23% (95%CI: 0.20 to 0.26%) lower grey 331

matter volume, and 0.09% (95%CI: 0.06 to 0.11%) lower white matter volume. Higher 332

cardiac troponin I level at baseline was associated with lower grey matter volume, but not 333

with white matter volume. People with cardiac troponin I concentrations >5.2 ng/L had 0.63% 334

(95%CI: 0.23 to 1.04%) lower grey matter volume and 18% (95%CI: 0 to 40%) increased 335

336 risk of hippocampal atrophy compared with those with cardiac troponin I <2.5 ng/L,

corresponding to an age effect of 2.7 and 3 years, respectively (Table 4). Cardiac troponin I 337

concentration was not associated with white matter hyperintensities. 338

339

Discussion 340

Our longitudinal study suggests that subclinical myocardial injury in midlife, indicated by 341 elevated cardiac troponin I levels, is associated with higher dementia risk. We have three key 342 findings. First, people with higher cardiac troponin I concentrations at baseline had faster 343 decline of cognition and were more likely to be diagnosed with dementia over a median 25 344 years of follow-up. Second, backward trajectory analysis showed that cardiac troponin I level 345 346 was consistently higher in those who developed dementia compared to those who did not between 7 and 25 years before diagnosis. The length of time suggests that higher cardiac 347 troponin I is unlikely to be due to prodromal changes, and it may be on the causal pathway. 348 Third, in the MRI substudy, people with increased cardiac troponin I at the midlife baseline 349 were more likely to have relatively low grey matter volume and hippocampal atrophy 15 350 years later. These three consistent findings involving repeated assessments with a high-351

sensitivity cardiac troponin I assay starting in midlife strengthen the evidence that myocardialinjury may directly or indirectly contribute to the aetiology of dementia.

354 Comparison with previous studies

Two published studies have examined the prospective association of cardiac troponin with 355 incident dementia.²⁰ The Atherosclerosis Risk in Communities (ARIC) study found that 356 elevated levels of high-sensitivity cardiac troponin T measured at mean age of 62.5 years 357 were associated with higher dementia incidence over 13 years of follow-up.¹⁰ The national 358 FINRISK 1997 study reported that high-sensitivity cardiac troponin I measured at a mean age 359 of 47.9 years was associated with incident dementia over 18 years of follow-up.²¹ Our study 360 had longer follow-up and larger effect size compared with FINRISK using high-sensitivity 361 troponin I (Abbott Architect), but a smaller effect size compared with the ARIC study using 362 363 high-sensitivity troponin T (Roche Elecsys). These previous studies were based on a single measurement of cardiac troponin. 364

Our novel contribution to the evidence is based on repeated measurements of cardiac troponin I over a 15-year period which allowed the backward trajectory before dementia diagnosis to be modelled. We observed an increased cardiac troponin level occurred as early as 25 years before dementia diagnosis. Further, our characterisation of cognitive decline, based on six assessments of cognitive function over 25 years substantiates the interpretation that subclinical myocardial injury is associated with long-run processes in the midlife preclinical period.

372 A few prospective studies found higher cardiac troponin T concentration at baseline was associated with faster annual decline in global cognition. However, these studies either had 373 cardiac troponin measured at older age $(>65 \text{ years})^{11,12,22}$ or had few repeated measurements 374 of cognitive function (<3 times),²³ or had a short follow-up time (<5 years).^{11,12} Consequently, 375 no previous study investigated the effect of the cardiac troponin at midlife on the subsequent 376 long-term cognitive trajectory until late life. Our study measured cardiac troponin I at a mean 377 age of 56 years and had up to 6 repeated measurements of cognitive function across 25 years 378 and found that cognitive performance was not significantly different in the 60s and 70s, but 379 started to diverge around age 80. This is consistent with the finding from the ARIC study that 380 cardiac troponin T measured at a mean age of 63 years was not associated with 15-year 381 change in cognitive function using only two repeated cognitive function measured 15 years 382 apart.23 383

Few population-based studies have examined the association between cardiac troponin and 384 structural brain changes, and cardiac troponin T assays were mostly used that have greater 385 imprecision than high-sensitivity cardiac troponin I assays at the low concentrations observed 386 in population studies.²⁴ A cross-sectional study using data from the Maastricht study found 387 that a higher cardiac troponin T concentration was associated with smaller grey matter 388 volume and greater white matter hyperintensity among participants aged 60 and above.²⁵ The 389 ARIC study reported that individuals with higher cardiac troponin T was associated with 390 MRI-defined silent brain infarcts and white matter lesions cross-sectionally and more white 391 matter lesions progression on the follow-up MRI 11 years later.²⁶ Our study used a high-392 sensitivity cardiac troponin I assay with consistent findings in regards to the smaller grey 393 matter in those with higher cardiac troponin levels. A potential explanation is that grey matter 394 is more susceptible to cerebral hypoperfusion caused by cardiac dysfunction as it has higher 395 metabolic demand compared with white matter. Our study, however, did not find cardiac 396 troponin to be associated with white matter hyperintensity. This is consistent with the 397 previous evidence from the Whitehall II study that the life Simple 7 cardiovascular health 398 score was not associated with white matter hyperintensities.⁵ A recent study using UK 399 Biobank, however, found that higher Life Essential 8 cardiovascular health score was 400 associated with lower white matter hyperintensity volume.²⁷ This reflects that cardiac 401 troponin may capture different aspects of cardiac dysfunction compared to cardiovascular 402 403 health scores. Different methods used to measure white matter hyperintensity may also explain these inconsistent observations. 404

405 Role of subclinical myocardial injury in dementia aetiology

Dementia and cardiovascular disease share risk factors such as hypertension and 406 hyperlipidemia.^{3,28–30} These risk factors may contribute to the heart-brain connection by 407 causing damage to vessels in both organs. Importantly, our analysis shows that higher cardiac 408 troponin was associated with higher dementia risk independent of hypertension and 409 hyperlipidaemia. Higher cardiac troponin is associated with increased risk of stroke,³¹ and 410 stroke is known to double the risk of dementia.³² Interestingly, the effect was only slightly 411 attenuated when adjusting for clinically diagnosed cardiovascular disease in our study, 412 indicating other mechanisms beyond occlusion of major arteries, such as cerebral small 413 vessel disease and cerebral hypoperfusion and hypoxia, may be involved.^{3,33} A previous 414 review concluded that cardiac troponins are more consistently linked to vascular brain lesions 415 than to neurodegenerative changes such as brain atrophy.² However, we found that cardiac 416

troponin was prospectively associated with brain atrophy. It is possible that vascular and
 neurodegenerative brain damage may overlap and develop in parallel³⁴ and cardiac troponin
 may provide insights into both pathologic processes.

420 Strengths and limitations

421 Our study, with a median follow-up of 25 years, is less susceptible to reverse causation. The

422 development of dementia involves a long prodromal period, and neuropathological

423 abnormality and change of biomarker levels can begin 15 to 20 years before clinical

424 diagnosis of dementia. No other population-based studies have measured cardiac troponin

level at midlife with a follow-up period of 20 years, which is critical to examine the

426 association between subclinical myocardial injury in midlife and incident dementia.

427 Another novel strength is the incorporation of repeated measurements of high-sensitivity

428 cardiac troponin I and modelling the backward trajectory of cardiac troponin before dementia

429 diagnosis. Previous studies only focused cardiac troponin level at one time point, and its

430 association with incident dementia depends on both when cardiac troponin was measured and

the length of the follow-up period. This conventional study design cannot determine the

432 length of time that cardiac troponin levels have been raised before dementia diagnosis.

433 Our results may underestimate the association as cardiac troponin is associated with mortality, although we would have picked up some of these people if dementia was recorded on the 434 death certificate. Troponin I levels can be elevated due to other causes that cardiac muscle 435 pathology such as intense exercise, but this would not be expected to increase the risk of 436 437 dementia. The population in Whitehall II are predominantly white, and generalisation of our results to other ethnicity groups should be cautious. We used one cardiac troponin I assay, 438 and validation of our results using other cardiac troponin assays is needed if measurement 439 were to be used in clinical practice to inform dementia risk. 440

441 Conclusion

Subclinical myocardial injury at midlife is associated with higher dementia incidence in later
life. Measurement of cardiac troponin I using a high-sensitivity assay in midlife may be
useful in the early identification of a population at risk of cognitive decline and dementia.

445

446 Acknowledgements

447 We thank all of the participating civil service departments and their welfare, personnel, and

- establishment officers; the British Occupational Health and Safety Agency; the British
- 449 Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and
- all members of the Whitehall II Study team at UCL and Oxford.

451 **Contributors**

- 452 YC and EJB conceptualised and designed the study. YC and MS did the statistical analysis.
- 453 YC wrote the first draft of the manuscript. All authors interpreted the data and critically
- 454 revised the manuscript. All authors approved the final version of the manuscript for
- submission. YC and EJB are the guarantors. The corresponding author attests that all listed
- 456 authors meet authorship criteria and that no others meeting the criteria have been omitted.

457 **Funding**

- 458 The Whitehall II study has been supported by grants from the Wellcome Trust, UK
- 459 (221854/Z/20/Z), the UK Medical Research Council (Y014154, K013351, R024227,
- 460 S011676); the British Heart Foundation (PG/11/63/29011, RG/13/2/30098, RG/16/11/32334);
- the British Health and Safety Executive; the British Department of Health; the National Heart,
- 462 Lung, and Blood Institute (R01HL036310); the National Institute on Aging, National
- 463 Institute of Health (R01AG013196, R01AG034454); the Economic and Social Research
- 464 Council (ES/J023299). The Whitehall II imaging substudy (KPE) was supported by the
- 465 Medical Research Council (G1001354), the HDH Wills 1965 Charitable Trust (English
- 466 Charity No 1117747), and the Gordon Edward Small's Charitable Trust (Scottish Charity No
- 467 SC008962). DMK is supported by the British Heart Foundation through an Intermediate
- 468 Basic Science Research Fellowship. NLM is supported by the British Heart Foundation
- through a Chair Award (CH/F/21/90010), Programme Grant (RG/20/10/34966), and a
- 470 Research Excellence Award (RE/24/130012). The study was supported by an investigator-
- initiated study grant from the Siemens Healthineers to the University of Edinburgh. YC is
- 472 supported by the Wellcome Early-Career Award (227639/Z/23/Z). EJB was supported by the
- 473 Economic and Social Research Council (ES/T014377).

474 Ethical approval

475 Written informed consent from participants and research ethics approvals were renewed at

- each contact. Ethical approval was from the University College London Hospital Committee
- 477 on the Ethics of Human Research (reference number 85/0938).

478 **Competing interests**

- 479 All authors have completed the ICMJE uniform disclosure form at
- 480 www.icmje.org/disclosure-of-interest/ and declare: support for the Whitehall II study from
- 481 the Wellcome Trust, the National Institute on Aging, NIH, the British Heart Foundation and
- 482 UK Medical Research Council; no financial relationships with any organisations that might
- 483 have an interest in the submitted work in the previous three years; no other relationships or
- 484 activities that could appear to have influenced the submitted work. KPE reports receiving
- 485 consulting fees for being in the expert panel for European Research Council, Flemish Science
- 486 Foundation, and European Science Foundation. JD reports consulting fees and honoraria
- 487 from Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi,
- 488 Takeda, Novo Nordisk, and Bayer. NLM reports honoraria from Abbott Diagnostics, Siemens
- 489 Healthineers, and Roche Diagnostics.

490 Transparency declaration

- 491 The manuscript is an honest, accurate, and transparent account of the study being reported.
- 492 No important aspects of the study have been omitted. Any discrepancies from the study as
- 493 originally planned (and, if relevant, registered) have been explained.

495 **References**

- 1Zhao B, Li T, Fan Z, *et al.* Heart-brain connections: Phenotypic and genetic insights from
 magnetic resonance images. *Science* 2023; **380**: abn6598.
- 498 2Jensen M, Zeller T, Twerenbold R, Thomalla G. Circulating cardiac biomarkers, structural
 499 brain changes, and dementia: Emerging insights and perspectives. *Alzheimers Dement* 2023;
 500 19: 1529–48.
- 3Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline.
 Nat Rev Cardiol 2015; 12: 267–77.
- 4Livingston G, Huntley J, Liu KY, *et al.* Dementia prevention, intervention, and care: 2024
 report of the Lancet standing Commission. *The Lancet* 2024; **404**: 572–628.
- 505 5 Sabia S, Fayosse A, Dumurgier J, *et al.* Association of ideal cardiovascular health at age 50
 506 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. *BMJ* 2019; 366:
 507 14414.
- 6Jefferson AL, Beiser AS, Himali JJ, *et al.* Low Cardiac Index Is Associated With Incident
 Dementia and Alzheimer Disease. *Circulation* 2015; **131**: 1333–9.
- 7Neumann JT, Twerenbold R, Weimann J, *et al.* Prognostic Value of Cardiovascular
 Biomarkers in the Population. *JAMA* 2024; **331**: 1898–909.
- 512 8Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk
- prediction in the general population: the BiomarCaRE consortium. *Eur Heart J* 2016; 37:
 2428–37.
- 9de Bakker M, Anand A, Shipley M, *et al.* Sex Differences in Cardiac Troponin Trajectories
 Over the Life Course. *Circulation* 2023; 147: 1798–808.
- 517 10 Schneider ALC, Rawlings AM, Sharrett AR, *et al.* High-sensitivity cardiac troponin T and
 518 cognitive function and dementia risk: the atherosclerosis risk in communities study. *Eur*519 *Heart J* 2014; **35**: 1817–24.
- 11 Bertens AS, Sabayan B, de Craen AJM, Van der Mast RC, Gussekloo J. High Sensitivity
 Cardiac Troponin T and Cognitive Function in the Oldest Old: The Leiden 85-Plus Study. J
- 522 *Alzheimers Dis* 2017; **60**: 235–42.
- 12 Wijsman LW, de Craen AJ, Trompet S, *et al.* High-sensitivity cardiac troponin T is
 associated with cognitive decline in older adults at high cardiovascular risk. *Eur J Prev Cardiol* 2016; 23: 1383–92.
- 13 Kimenai DM, Anand A, de Bakker M, *et al.* Trajectories of cardiac troponin in the
 decades before cardiovascular death: a longitudinal cohort study. *BMC Medicine* 2023; 21:
 216.
- 14 Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis
 of age-related cognitive decline (e–Pub ahead of print)(CME). *Neurology* 2010; **75**: 1070–8.

- 15 Filippini N, Zsoldos E, Haapakoski R, et al. Study protocol: the Whitehall II imaging sub-531 532 study. BMC Psychiatry 2014; 14: 159. 16 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 533 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987; 149: 351-6. 534 17 Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in 535 'probable' Alzheimer's disease and normal ageing: diagnostic value and 536 neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-72. 537 18 Bloomberg M, Dugravot A, Dumurgier J, et al. Sex differences and the role of education 538 539 in cognitive ageing: analysis of two UK-based prospective cohort studies. Lancet Public *Health* 2021; **6**: e106–15. 540 19 Proust-Lima C, Philipps V, Liquet B. Estimation of Extended Mixed Models Using Latent 541 Classes and Latent Processes: The R Package lcmm. Journal of Statistical Software 2017; 542 543 **78**: 1–56. 20 Zonneveld MH, Abbel D, le Cessie S, Jukema JW, Noordam R, Trompet S. Cardiac 544 545 Troponin, Cognitive Function, and Dementia: A Systematic Review. Aging Dis 2023; 14: 386-97. 546 21 Tynkkynen J, Hernesniemi JA, Laatikainen T, et al. High-sensitivity cardiac troponin I 547 548 and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study. J Neurol 2017; 264: 503-11. 549 22 von Rennenberg R, Liman T, Nolte CH, et al. High-Sensitivity Cardiac Troponin T and 550 Cognitive Decline in Older Adults: Results of the Berlin Aging Study II. Gerontology 2023; 551 **69**: 140–8. 552 23 Pokharel Y, Mouhanna F, Schneider ALC, et al. High-Sensitive Troponin T, Natriuretic 553 Peptide, and Cognitive Change. J Am Geriatr Soc 2019; 67: 2353-61. 554 555 24 Apple FS, Collinson PO, for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays. 556 Clinical Chemistry 2012; 58: 54-61. 557 25 Veugen MGJ, Henry RMA, Brunner-La Rocca H-P, et al. Cross-Sectional Associations 558 Between Cardiac Biomarkers, Cognitive Performance, and Structural Brain Changes Are 559 Modified by Age. Arterioscler Thromb Vasc Biol 2018; 38: 1948-58. 560 26 Dadu RT, Fornage M, Virani SS, et al. Cardiovascular Biomarkers and Subclinical Brain 561 Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2013; 44: 1803-562 8. 563 27 Zhou R, Chen H-W, Li F-R, Zhong Q, Huang Y-N, Wu X-B. 'Life's Essential 8' 564 Cardiovascular Health and Dementia Risk, Cognition, and Neuroimaging Markers of Brain 565 Health. J Am Med Dir Assoc 2023; 24: 1791-7. 566 28 Janssen E, de Leeuw F-E. Getting to the Heart of the Heart-Brain Connection. Neurology 567 568 2023; 101: 57-8. 18

- 29 Chen Y, Araghi M, Bandosz P, et al. Impact of Hypertension Prevalence Trend on 569
- Mortality and Burdens of Dementia and Disability in England and Wales to 2060: 570
- Modelling Study. 2023; published online Feb 17. DOI:10.2139/ssrn.4356790. 571
- 30 Abell JG, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure 572
- 573 and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J 2018; 39: 3119-25. 574
- 31 Broersen LHA, Stengl H, Nolte CH, et al. Association Between High-Sensitivity Cardiac 575 Troponin and Risk of Stroke in 96 702 Individuals: A Meta-Analysis. Stroke 2020; 51: 576 1085–93. 577
- 32 Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and 578 dementia risk: A systematic review and meta-analysis. Alzheimers Dement 2018; 14: 1416– 579 580 26.
- 581 33 Zhao D, Guallar E, Qiao Y, et al. Intracranial Atherosclerotic Disease and Incident
- Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation 2024; 150: 582 838-47. 583
- 34 Song R, Pan K-Y, Xu H, et al. Association of cardiovascular risk burden with risk of 584
- 585 dementia and brain pathologies: a population-based cohort study. Alzheimers Dement 2021; **17**: 1914–22. 586

Figure legends 588

Figure 1 Cognitive trajectories from age 50 to 89 years by levels of high-sensitivity cardiac troponin I 589

at baseline stratified by birth cohort. Predicted cognitive scores estimated from a mixed model (model 590

terms: sex, ethnicity, education level, occupational position, birth cohort, age, age², and interactions of 591 all covariates with age and age²). P for difference in trajectory between different cardiac troponin

592 593 levels: 0.0012

594

Figure 2 Averaged predicted trajectories of high-sensitivity cardiac troponin I (ng/L, log2 transformed) 595

for 695 incident cases of dementia and 2780 matched controls over 25 years preceding diagnosis of 596

597 dementia estimated from a latent process mixed model. Nested case-control design matching with age,

598 sex and education level. Dashed lines represent 95% CIs. P for difference in trajectory between cases

599 and controls: 0.12

Table 1 Characteristics of the study sample 601

	High-sensitivity cardiac troponin I at baseline		Dementia status at the end of follow-up		
	≤3.4 ng/L (n=3417)	>3.4 ng/L (n=2568)	No dementia (n=5379)	Dementia (n=606)	Total population (n=5985)
Age, years	55.3 (5.8)	57.5 (6.1)	55.7 (5.9)	61.1 (5.1)	56.2 (6.0)
Women	1351 (39.5)	398 (15.5)	1539 (28.6)	210 (34.7)	1749 (29.2)
Ethnicity, White	3142 (92.0)	2350 (91.5)	4960 (92.2)	532 (87.8)	5492 (91.8)
Education					
Less than secondary school	1277 (37.4)	852 (33.2)	1847 (34.3)	282 (46.5)	2129 (35.6)
Secondary school University	890 (26.0) 1189 (34.8)	701 (27.3) 958 (37.3)	1455 (27.0) 1971 (36.6)	136 (22.4) 176 (29.0)	1591 (26.6) 2147 (35.9)
Occupation position					
Low Intermediate High	520 (15.2) 1506 (44.1) 1347 (39.4)	260 (10.1) 1036 (40.3) 1245 (48.5)	646 (12.0) 2308 (42.9) 2361 (43.9)	134 (22.1) 234 (38.6) 231 (38.1)	780 (13.0) 2542 (42.5) 2592 (43.3)
Alcohol consumption					
Non-drinkers Moderate heavy	556 (16.3) 1960 (57.4) 788 (23.1)	331 (12.9) 1539 (59.9) 617 (24.0)	757 (14.1) 3175 (59.0) 1271 (23.6)	130 (21.5) 324 (53.5) 134 (22.1)	887 (14.8) 3499 (58.5) 1405 (23.5)
Smoking status					
Never Former Current Physical activity, Hours	1679 (49.1) 1300 (38.0) 382 (11.2)	1264 (49.2) 1079 (42.0) 183 (7.1)	2644 (49.2) 2128 (39.6) 515 (9.6)	299 (49.3) 251 (41.4) 50 (8.3)	2943 (49.2) 2379 (39.7) 565 (9.4)
per week Low Moderate high	1129 (33.0) 588 (17.2) 1615 (47.3)	634 (24.7) 379 (14.8) 1484 (57.8)	1564 (29.1) 878 (16.3) 2791 (51.9)	199 (32.8) 89 (14.7) 308 (50.8)	1763 (29.5) 967 (16.2) 3099 (51.8)
Diabetes	94 (2.8)	63 (2.5)	129 (2.4)	28 (4.6)	157 (2.6)
BMI, kg/m ²	25.9 (4.0)	26.4 (3.8)	26.1 (3.9)	26.3 (4.1)	26.1 (3.9)
SBP, mmHg	121 (15.3)	127 (17.5)	123 (16.5)	126 (16.6)	123 (16.5)
DBP, mmHg	76.4 (9.9)	79.0 (11.2)	77.6 (10.5)	77.4 (10.4)	77.5 (10.5)
Glucose, mmol/L	5.2 (1.2)	5.3 (1.2)	5.2 (1.2)	5.4 (1.6)	5.2 (1.2)
Total cholesterol, mmol/L	5.9 (1.0)	5.9 (1.1)	5.9 (1.0)	6.1 (1.1)	5.9 (1.1)

602 Values are means (SDs) for continuous variables and numbers (percentages) for categorical variables

604 Table 2 Association between high-sensitivity cardiac troponin I at baseline (1997-99) and incident 605 dementia during 25 years of follow-up

Cardiac troponin I, ng/L	No of cases/total No	HR (95% CI)
<2.5	158/2135	1.00 (reference)
2.5-3.4	133/1282	1.22 (0.96,1.54)
3.5-5.2	150/1281	1.34 (1.06,1.70)
>5.2	165/1287	1.43 (1.13,1.80)

606 The model was adjusted for age, sex, ethnicity, education, occupational position, smoking status,

607 alcohol consumption, physical activity, BMI, systolic blood pressure, diastolic blood pressure,

608 glucose, and total cholesterol.

Table 3 Association of high-sensitivity cardiac troponin I with cognitive performance at age 60, 70,

610 80, and 90 years.

Difference in cognitive function					
	Age 60	Age 70	Age 80	Age 90	
Cardiac troponin I, ng/L					
<2.5	ref	ref	ref	ref	
2.5-3.4	0 (-0.05,0.05)	-0.04 (-0.09,0.02)	-0.03 (-0.11,0.04)	0 (-0.15,0.16)	
3.5-5.2	-0.02 (-0.08,0.03)	-0.06 (-0.11,0)	-0.06 (-0.14,0.01)	-0.05 (-0.21,0.10)	
>5.2	0 (-0.06,0.05)	-0.04 (-0.09,0.02)	-0.10 (-0.18,-0.02)	-0.19 (-0.35,-0.03)	

611

Table 4 Association between high-sensitivity cardiac troponin I at phase 5 (1997-99) and structural brain volume 15 years later: Whitehall II imaging substudy (n=641)

Cardiac troponin I, ng/L		Total brain volume (Grey matter + White matter) (% total intracranial volume)	Grey matter volume (% total intracranial volume)	Hippocampal atrophy (Scheltens score summed across both sides, range 0-8)	
	No	Difference (95%CI)	Difference (95%CI)	Ratio of the score (95%CI)	
<2.5	220	0 (ref)	0 (ref)	1 (ref)	
2.5-3.4	144	-0.34 (-0.83,0.14)	-0.44 (-0.83,-0.04)	1.03 (0.87,1.23)	
3.5-5.2	136	-0.38 (-0.88,0.11)	-0.62 (-1.03,-0.22)	1.16 (0.98,1.38)	
>5.2	141	-0.65 (-1.14,-0.15)	-0.63 (-1.04,-0.23)	1.18 (1,1.40)	
Every doubling in cardiac troponin I	641	-0.10 (-0.26,0.06)	-0.13 (-0.26,0.00)	1.03 (0.98,1.09)	

For total brain volume, grey matter volume and white matter volume, linear regression models were used adjusted for age, sex, ethnicity, education level, occupational position, smoking status, alcohol consumption, and magnetic resonance imaging scanner.

For total white matter hyperintensities and hippocampal atrophy, Poisson regressions were used adjusted for age, sex, ethnicity, education level, occupational position, smoking status, alcohol consumption, and magnetic resonance imaging scanner.

We did not find significant results for white matter volume and total white matter hyperintensities.





Years before dementia onset